Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization

Cancer Science

Volumn 99, Issue 5, 2008, Pages 986-994

  Suzuki, Ayako ^a,b   Shibata, Tatsuhiro ^c   Shimada, Yutaka ^d   Murakami, Yoshinori ^e   Horii, Akira ^f   Shiratori, Keiko ^b   Hirohashi, Setsuo ^c   Inazawa, Johji ^a,g   Imoto, Issei ^a,g  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN SMURF1; SMURF1 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CANCER CELL CULTURE; CHROMOSOME 7Q; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENE MAPPING; GENE OVEREXPRESSION; GENOME ANALYSIS; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR CLONING; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; BACTERIAL ARTIFICIAL CHROMOSOME; CHROMOSOME 7; CHROMOSOME MAP; EVALUATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENETICS; GENOMICS; METABOLISM; METHODOLOGY; PANCREAS TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; CHROMOSOME MAPPING; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CHROMOSOMES, HUMAN, PAIR 7; GENE DOSAGE; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; UBIQUITIN-PROTEIN LIGASES;

EID: 43649083327     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00779.x     Document Type: Article

References (40)

1. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002; 2: 897-909.
2. Matsuno S, Egawa S, Fukuyama S et al. Pancreatic cancer registry in Japan: 20 years of experience. Pancreas 2004; 28: 219-30.
3. Murr MM, Sarr MG, Oishi AJ, van Heereden JA. Pancreatic cancer. CA Cancer J Clin 1994; 44: 304-18.
4. Grunewald K, Lyons J, Frohlich A et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989; 43: 1037-41.
5. Moore PS, Sipos B, Orlandini S et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 2001; 439: 798-802.
6. Solinas-Toldo S, Wallrapp C, Muller-Pillasch F, Bentz M, Gress T, Lichter P. Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. Cancer Res 1996; 56: 3803-7.
7. Mahlamaki EH, Hoglund M, Gorunova L et al. Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer. Genes Chromosomes Cancer 1997; 20: 383-91.
8. Schleger C, Arens N, Zentgraf H, Bleyl U, Verbeke C. Identification of frequent chromosomal aberrations in ductal adenocarcinomas of the pancreas by comparative genomic hybridization (CGH). J Pathol 2000; 191: 27-32.
9. Pinkel D, Segraves R, Sudar D et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998; 20: 207-11.
10. Inazawa J, Inoue J, Imoto I. Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci 2004; 95: 559-63.
11. Aguirre AJ, Brennan C, Bailey G et al. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci USA 2004; 101: 9067-72.
12. Heidenblad M, Schoenmakers EF, Jonson T et al. Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines. Cancer Res 2004; 64: 3052-9.
13. Holzmann K, Kohlhammer H, Schwaenen C et al. Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes. Cancer Res 2004; 64: 4428-33.
14. Mahlamaki EH, Kauraniemi P, Monni O, Wolf M, Hautaniemi S, Kallioniemi A. High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer. Neoplasia 2004; 6: 432-9.
15. Bashyam MD, Bair R, Kim YH et al. Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia 2005; 6: 556-62.
16. Nowak NJ, Gaile D, Conroy JM et al. Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet Cytogenet 2005; 161: 36-50.
17. Gysin S, Rickert P, Kastury K, McMahon M. Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines. Genes Chromosomes Cancer 2005; 44: 37-51.
18. Loukopoulos P, Shibata T, Katoh H et al. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci 2007; 98: 392-400.
19. Harada T, Chelala C, Bhakta V et al. Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene 2007: [Epub ahead of print].
20. Maitra A, Wistuba II, Virmani AK et al. Enrichment of epithelial cells for molecular studies. Nat Med 1999; 5: 459-63.
21. Imoto I, Yang ZQ, Pimkhaokham A et al. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res 2001; 61: 6629-34.
22. Saito-Ohara F, Imoto I, Inoue J et al. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 2003; 63: 1876-83.
23. Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA, Tsao MS. Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol 1996; 148: 1763-70.
24. Noguchi M, Furuya S, Takeuchi T, Hirohashi S. Modified formalin and methanol fixation methods for molecular biological and morphological analyses. Pathol Int 1997; 47: 685-91.
25. Tanabe C, Aoyagi K, Sakiyama T et al. Evaluation of a whole-genome amplification method based on adaptor-ligation PCR of randomly sheared genomic DNA. Genes Chromosomes Cancer 2003; 38: 168-76
26. Takada H, Imoto I, Tsuda H et al. Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization. Cancer Sci 2005; 96: 100-10.
27. Wang HR, Zhang Y, Ozdamar B et al. Regulation of cell polarity and protrusion formation by targeting RhoA for degradation. Science 2003; 302: 1775-9.
28. Yu W, Imoto I, Inoue J, Onda M, Emi M, Inazawa J. A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene 2007; 26: 1178-87.
29. Sonoda I, Imoto I, Inoue J et al. Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous-cell carcinoma. Cancer Res 2004; 64: 3741-7.
30. Yamada H, Sakamoto H, Taira M et al. Amplifications of both c-Ki-ras with a point mutation and c-myc in a primary pancreatic cancer and its metastatic tumors in lymph nodes. Jpn J Cancer Res 1986; 77: 370-5.
31. Cheng JQ, Ruggeri B, Klein WM et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996; 93: 3636-41.
32. Izumi H, Inoue J, Yokoi S et al. Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum Mol Genet 2005; 14: 1-11.
33. Kikuchi R, Tsuda H, Kanai Y et al. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor-suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res 2007; 67: 7095-105.
34. Garber K. New insights into oncogene addiction found. J Natl Cancer Inst 2007; 99: 264-5.
35. Ebisawa T, Fukuchi M, Murakami G et al. Smurf1 interacts with transforming growth factor-β type I receptor through Smad7 and induces receptor degradation. J Biol Chem 2001; 276: 12.477-80.
36. Moren A, Imamura T, Miyazono K, Heldin CH, Moustakas A. Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases. J Biol Chem 2005; 280: 22.115-23.
37. Ijichi H, Otsuka M, Tateishi K et al. Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta. Oncogene 2004; 23: 1043-51.
38. Sahai E, Garcia-Medina R, Pouyssegur J, Vial E. Smurf1 regulates tumor cell plasticity and motility through degradation of RhoA leading to localized inhibition of contractility. J Cell Biol 2007; 176: 35-42.
39. McMahon SB, Van Buskirk HA, Dugan KA, Copeland TD, Cole MD. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 1998; 94: 363-74.
40. Herceg Z, Hulla W, Gell D et al. Disruption of Trrap causes early embryonic lethality and defects in cell cycle progression. Nat Genet 2001; 29: 206-11.